The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
The portfolio includes foundational patents on the production, composition, and commercial use of NR
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Full approval will depend on verification of clinical benefit in a confirmatory trial
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
Subscribe To Our Newsletter & Stay Updated
